A. *In vivo* therapeutic efficacy study

Sample collection and treatment:

- Subjects enrolled on D0, administered CQ (N = 125)
  - Withdraws (n = 5);
  - Loss to follow up (n = 13)
- Completed 28-day follow up, administered PQ (n = 107)
  - Pv+ on D0 only (n = 74, 74 isolates)
  - Pv+ on D0, 2 only (n = 15, 30 isolates)
  - Pv+ on D0, 2, 7 only (n = 1, 2 isolates)
  - Pv+ on D0, 2, 7, Rec (n = 1, 3 isolates)
    - PQ completed (n = 1)
    - PQ completed (n = 2)
  - Pv+ D0 and Rec (n = 14, 28 isolates)
    - PQ completed (n = 14)
    - PQ not completed (n = 7)

Genotype processing:

- Selected for genotyping (D0, n = 33; D2, n = 19; DRec, n = 17)
  - Pvmdr1 sequencing (n = 69)
    - Failed to amplify (D2, n = 19; DRec, n = 2)
    - 958M/Y976/1076L (D0, n = 33; DRec, n = 14)
    - 958M/Y976/F1076 (DRec, n = 1)
  - MS fragment analysis (n = 50)
    - Failed to amplify (D2, n = 19)
    - Full allelic haplotypes (D0, n = 33; DRec, n = 17)

B. *In vitro* drug assay

Sample collection and treatment:

- Subjects enrolled, administered CQ (N = 96)
  - Isolates excluded due to time delay in processing (n = 15)
- Isolates processed (n = 81)
  - Invalid IC\textsubscript{50} results (n = 13)
  - Valid IC\textsubscript{50} results (n = 68)
- Selected for genotyping (n = 20)
  - Pvmdr1 sequencing (n = 20)
    - Failed to amplify (n = 2)
    - 958M/Y976/1076L (n = 17)
    - 958M/Y976/F1076 (n = 1)
  - MS fragment analysis (n = 20)
    - Full allelic haplotypes (n = 20)